 Quinolines
"Quinolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011804
|
| MeSH Number(s) |
D03.633.100.810
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinolines".
Below are MeSH descriptors whose meaning is more specific than "Quinolines".
This graph shows the total number of publications written about "Quinolines" by people in this website by year, and whether "Quinolines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 2000 | 2 | 0 | 2 | | 2003 | 2 | 0 | 2 | | 2004 | 3 | 1 | 4 | | 2005 | 1 | 1 | 2 | | 2006 | 5 | 3 | 8 | | 2007 | 2 | 0 | 2 | | 2008 | 4 | 1 | 5 | | 2009 | 2 | 2 | 4 | | 2010 | 3 | 3 | 6 | | 2011 | 3 | 5 | 8 | | 2012 | 2 | 3 | 5 | | 2013 | 3 | 2 | 5 | | 2014 | 6 | 2 | 8 | | 2015 | 3 | 3 | 6 | | 2016 | 3 | 1 | 4 | | 2017 | 1 | 0 | 1 | | 2018 | 2 | 1 | 3 | | 2019 | 3 | 0 | 3 | | 2020 | 1 | 0 | 1 | | 2021 | 4 | 4 | 8 | | 2022 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Quinolines" by people in Profiles.
-
Brose MS, Smit JWA, Lin CC, Tori M, Bowles DW, Worden F, Shen DH, Huang SM, Tsai HJ, Alevizaki M, Peeters RP, Takahashi S, Rumyantsev P, Guan R, Babajanyan S, Ozgurdal K, Sugitani I, Pitoia F, Lamartina L. Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI). Thyroid. 2022 09; 32(9):1059-1068.
-
Bertol BC, Bales ES, Calhoun JD, Mayberry A, Ledezma ML, Sams SB, Orlicky DJ, Donadi EA, Haugen BR, French JD. Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer. Thyroid. 2022 02; 32(2):153-163.
-
Straign DM, Ihle CL, Provera MD, Owens P. Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease. Front Endocrinol (Lausanne). 2021; 12:769316.
-
Shaughnessy CA, Zeitlin PL, Bratcher PE. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Sci Rep. 2021 10 06; 11(1):19810.
-
Barry PJ, Mall MA, ?lvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. N Engl J Med. 2021 08 26; 385(9):815-825.
-
Szarek M, Needle MN, Rini BI, Pal SK, McDermott DF, Atkins MB, Hutson TE, Escudier BJ. Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. Clin Genitourin Cancer. 2021 10; 19(5):468.e1-468.e5.
-
Stoen E, Kagihara J, Shagisultanova E, Fisher CM, Nicklawsky A, Kabos P, Borges VF, Diamond JR. Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval. Breast Cancer Res Treat. 2021 Jun; 187(3):883-891.
-
Griese M, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Taylor-Cousar JL, Withers NJ, Moskowitz SM, Daines CL. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2021 02 01; 203(3):381-385.
-
Kolaric A, Germe T, Hrast M, Stevenson CEM, Lawson DM, Burton NP, V?r?s J, Maxwell A, Minovski N, Anderluh M. Potent DNA gyrase inhibitors bind asymmetrically to their target using symmetrical bifurcated halogen bonds. Nat Commun. 2021 01 08; 12(1):150.
-
Awolade P, Cele N, Ebenezer O, Kerru N, Gummidi L, Gu L, Palma G, Kaur M, Singh P. Synthesis of 1H-1,2,3-Triazole-Linked Quinoline-Isatin Molecular Hybrids as Anti-Breast Cancer and Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) Agents. Anticancer Agents Med Chem. 2021; 21(10):1228-1239.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|